博瑞迪 provides low-cost genotyping and targeted gene capture sequencing solutions focused on molecular breeding for plants and animals. The company owns two proprietary targeted capture technology systems, GenoPlexs and GenoBaits. Its technology emphasizes high capture efficiency, flexible marker and capture types, and low-cost customized services for customers. The article reports that 博瑞迪 completed a RMB 250 million Series B financing. Participating investors and deal advisors are listed in the financing announcement. The article does not disclose operating metrics, founding year, or detailed future plans. Boruidi Bio builds a fully domestic, closed‑loop molecular breeding detection platform spanning database, algorithms, reagents and automated testing equipment, anchored on its proprietary liquid‑phase capture sequencing and GBTS technical system. The company positions itself as a third‑party service platform providing standardized sampling, high‑throughput detection and bioinformatics to breeding enterprises, and reports enabling customers to shorten breeding cycles by >50%, raise selection accuracy by 20–30%, and cut costs by over 90%. Boruidi says it has supported nearly 300 breeding units across more than 60 species and amassed roughly 2.5 PB of genetic data and ~800 billion variant data points. The team is led by founder Zhang Jia‑nan and includes members with experience from BGI, 23mofang, Wageningen, Cornell and other institutions. Recent plans include continued R&D and iterative upgrades, construction of a gene‑editing platform, and domestic and overseas business expansion. Financially the company has completed multiple financings in the past 18 months totaling over ¥100M, and will use new proceeds to accelerate technology development and market expansion.

Total raised

$49M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2024